Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorFernández-Hidalgo, Nuria
dc.contributor.author Bellmunt-Montoya, Sergi
dc.contributor.authorPalau Gauthier, Marta
dc.contributor.authorMuñoz, Estela
dc.contributor.authorGomis Rodriguez, Javier
dc.contributor.authorGavaldà, Joan
dc.date.accessioned2023-06-27T09:33:00Z
dc.date.available2023-06-27T09:33:00Z
dc.date.issued2023-02-07
dc.identifier.citationTello-Díaz C, Palau M, Muñoz E, Gomis X, Gavaldà J, Fernández-Hidalgo N, et al. Methicillin-Susceptible Staphylococcus aureus Biofilm Formation on Vascular Grafts: an In Vitro Study. Microbiol Spectr. 2023 Feb 7;11(2):e0393122.
dc.identifier.issn2165-0497
dc.identifier.urihttps://hdl.handle.net/11351/9903
dc.descriptionStaphylococcus aureus; Biofilm; Infection
dc.description.abstractThe aim of this study was to quantify in vitro biofilm formation by methicillin-susceptible Staphylococcus aureus (MSSA) on the surfaces of different types of commonly used vascular grafts. We performed an in vitro study with two clinical strains of MSSA (MSSA2 and MSSA6) and nine vascular grafts: Dacron (Hemagard), Dacron-heparin (Intergard heparin), Dacron-silver (Intergard Silver), Dacron-silver-triclosan (Intergard Synergy), Dacron-gelatin (Gelsoft Plus), Dacron plus polytetrafluoroethylene (Fusion), polytetrafluoroethylene (Propaten; Gore), Omniflow II, and bovine pericardium (XenoSure). Biofilm formation was induced in two phases: an initial 90-minute adherence phase and a 24-hour growth phase. Quantitative cultures were performed, and the results were expressed as log10 CFU per milliliter. The Dacron-silver-triclosan graft and Omniflow II were associated with the least biofilm formation by both MSSA2 and MSSA6. MSSA2 did not form a biofilm on the Dacron-silver-triclosan graft (0 CFU/mL), and the mean count on the Omniflow II graft was 3.89 CFU/mL (standard deviation [SD] 2.10). The mean count for the other grafts was 7.01 CFU/mL (SD 0.82). MSSA6 formed a biofilm on both grafts, with 2.42 CFU/mL (SD 2.44) on the Dacron-silver-triclosan graft and 3.62 CFU/mL (SD 2.21) on the Omniflow II. The mean biofilm growth on the remaining grafts was 7.33 CFU/mL (SD 0.28). The differences in biofilm formation on the Dacron-silver-triclosan and Omniflow II grafts compared to the other tested grafts were statistically significant. Our findings suggest that of the vascular grafts we studied, the Dacron-silver-triclosan and Omniflow II grafts might prevent biofilm formation by MSSA. Although further studies are needed, these grafts seem to be good candidates for clinical use in vascular surgeries at high risk of infections due to this microorganism. IMPORTANCE The Dacron silver-triclosan and Omniflow II vascular grafts showed the greatest resistance to in vitro methicillin-susceptible Staphylococcus aureus biofilm formation compared to other vascular grafts. These findings could allow us to choose the most resistant to infection prosthetic graft.
dc.language.isoeng
dc.publisherAmerican Society for Microbiology
dc.relation.ispartofseriesMicrobiology Spectrum;11(2)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectBiofilms
dc.subjectVasos sanguinis - Empelts
dc.subjectMalalties bacterianes
dc.subjectInfecció
dc.subjectPròtesis
dc.subject.meshVascular Grafting
dc.subject.meshProsthesis-Related Infections
dc.subject.meshBiofilms
dc.titleMethicillin-Susceptible Staphylococcus aureus Biofilm Formation on Vascular Grafts: an In Vitro Study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1128/spectrum.03931-22
dc.subject.decsinjerto vascular
dc.subject.decsinfecciones relacionadas con prótesis
dc.subject.decsbiopelículas
dc.relation.publishversionhttps://doi.org/10.1128/spectrum.03931-22
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Tello-Díaz C] Department of Vascular and Endovascular Surgery, Hospital de la Santa Creu i Sant Pau, Institute of Biomedical Research (II-B Sant Pau), CIBER CV, Barcelona, Spain. Departament de Cirurgia i Ciències Morfològiques, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Palau M, Gomis X, Gavaldà J] Laboratori de Resistència Antimicrobiana, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fernández-Hidalgo N] CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Red Española de Investigación en Patología Infecciosa (REIPI RD16/0016/0003), Instituto de Salud Carlos III, Madrid, Spain. [Bellmunt-Montoya S] Departament de Cirurgia i Ciències Morfològiques, Universitat Autònoma de Barcelona, Bellaterra, Spain. Laboratori de Resistència Antimicrobiana, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Servei d’Angiologia, Cirurgia Vascular i Endovascular, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid36749062
dc.identifier.wos000937345400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record